Zeposia Generic: When Will Generic Ozanimod Be Available?
This page is aggregated from FDA records, court filings and company announcements. Coded and designed by Dr. Brian Staiger, PharmD, BCPS
Updated October 9, 2026 How we build our data
Zeposia Generic at a Glance
Four quick answers from FDA records and our estimate.
- When is the first generic expected? 2033 to 2034 A wide window Why then?
- Has the FDA approved a generic? Not yet None in the FDA’s records yet Why not yet?
- When does the last patent end? September 2038 5 patents listed with the FDA Why is a generic expected sooner?
- Can you buy a generic today? Not yet No company lists one for sale
Generic ozanimod hydrochloride is expected to be available between 2033 and 2034. None is for sale yet.
Why 2033 to 2034?
The brand company and a generic maker settled their patent fight and agreed on when a generic can launch. We rate it probable: more likely than not, but it can still move.
If Zeposia’s last patent runs to September 2038, how can a generic come sooner?
The patent that runs to September 2038 (11,680,050) covers the active ingredient, the product’s formulation and a way of using it. A generic can still come sooner if a court rules a patent invalid or not infringed, or if the companies settle on an earlier date. Here, a settlement between the companies sets the date. Generic companies have been challenging Zeposia’s patents with the FDA since March 2024. That is why the expected month comes before the last protection ends. See the road to a generic
Why hasn’t the FDA approved a generic yet?
That is normal before a launch. The FDA usually can’t give a generic its final approval while a patent or exclusivity still blocks it, so final approval often comes close to the day the generic can be sold. No company holds a “tentative” approval yet either (the FDA’s word for a generic that is ready but still blocked).
Will the generic cost less?
Usually, and more so as more companies sell one. 2 companies have applied to the FDA to make it. In the FDA’s study of past launches, pharmacies paid about 44% less once two companies sold a generic. See the price pattern
What should I do now?
Keep taking Zeposia as prescribed. When a generic arrives, your pharmacy may switch you to it automatically, and it may look different. What a generic means for you
Our month is only an estimate based on available information, so we never name a day.
Zeposia by the Numbers
- Reason
- Settlement between companiesThe brand company and a generic maker settled their patent fight and agreed on when a generic can launch.
- How sure
- Probable More likely than not, but it can still move.
- Price competition
- Moderate 2 companies have filed, 2 first in line
- Brand sales
- $741M a yearBig seller
- FDA approved 2020 March 2020 FDA Orange Book
- Patents listed 5 last runs to September 2038 A generic is expected sooner, between 2033 and 2034. See why FDA Orange Book
- Medicare Part D spent $119.2M in 2025, for 1,475 people CMS Part D Spending by Drug
- Medicaid prescriptions 5,162 in the last four reported quarters, $52.3M CMS Medicaid drug utilization, to Q1 2026
Zeposia’s Road to a Generic
Zeposia has had the market to itself since the FDA approved it in March 2020 (Bristol Myers Squibb Co). Its FDA protection (new clinical information) runs to August 2027. Its 5 listed patents run to September 2038. Generic companies have challenged its patents with the FDA since March 2024.
The first generic of Zeposia is expected between 2033 and 2034.
Why that month: the brand company and a generic maker settled their patent fight and agreed on when a generic can launch.
Why a Generic Can Come Before September 2038
The last listed patent runs to September 2038; a court ruling or a settlement can bring a generic sooner. Dr. Brian explains
Each bar runs from the brand’s approval to the day that protection ends. The green band is our projection for the first generic: a month, never a day, because legal dates move and a generic reaches shelves days to weeks after it is allowed. Sources: FDA Orange Book; the expected month from court records and company announcements.
Zeposia Patents and FDA Protections
Every patent and exclusivity the FDA Orange Book lists for Zeposia’s own applications. A protection running past the expected month does not mean the date is wrong: a settlement or a court ruling can let a generic in before a patent ends, and a patent on one formulation or use does not block every generic.
| Patent | What it covers | Protects until | Status |
|---|---|---|---|
| 8,796,318 | The active ingredient; the product’s formulation | May 2029 | Active |
| 9,382,217 | A way of using it (U-2774) | May 2029 | Active |
| 10,239,846 | A way of using it (U-3740) | November 2030 | Active |
| 8,481,573 | The active ingredient; the product’s formulation; a way of using it (U-2774) | March 2033 | Active |
| 11,680,050 | The active ingredient; the product’s formulation; a way of using it (U-2774, U-3740) | September 2038 | Active |
| Exclusivity | What it means | Ends | Status |
|---|---|---|---|
| New clinical information M-309 | Three years of protection for a change backed by new clinical studies. | August 2027 | Active |
Source: FDA Orange Book, application 209899. Patent numbers open the patent on Google Patents.
Patent Challenges to Zeposia
The first patent challenge to Zeposia reached the FDA in March 2024, from 3 companies on that first day. The FDA has not approved a first challenger’s generic yet.
What Is a Patent Challenge?
A generic company that wants to sell its version before Zeposia’s patents run out can tell the FDA that a patent is invalid, or that its version does not infringe it. The FDA calls this a “Paragraph IV certification.” The brand company usually sues, and the FDA then generally cannot approve that generic for up to 30 months while the case runs. To reward going first, the companies that challenge first can get a 180-day head start: the FDA cannot approve the generics that came after them until it ends.
| Product | First challenged | Companies that day | 180-day head start | First challenger’s generic | Challenged patents run to | |
|---|---|---|---|---|---|---|
| Approved | On sale | |||||
| Capsules, 0.23 mg, 0.46 mg and 0.92 mg | March 2024 | 3 companies | No decision yet | Not yet | Not yet | September 2038 |
Source: the FDA’s Paragraph IV Patent Certifications list, as of September 2026. The FDA began posting the 180-day decisions and the first challenger’s approval and first sale in June 2019: an older entry it has not updated since reads “Not posted”, and “Not yet” means the list records no such event. “Companies that day” is the FDA’s count of challenges that arrived on the first day.
Who Is Lined Up to Make Generic Ozanimod Hydrochloride
Three steps stand between a brand and a generic you can buy: a company applies to the FDA, the FDA approves it, and the company starts selling it.
Applied to the FDA
2 companies have applied to the FDA to make generic ozanimod hydrochloride.
The FDA names a company only once it approves its application, even tentatively, and it has not done that for these yet, so the companies are not named here. Names often come out in the brand company’s patent lawsuits or in the companies’ own announcements.
First in line. 2 of them were first in line, both filing on the first day any company did: they can share 180 days on the market before the other generics, which is why being first matters.
Generic companies have challenged Zeposia’s patents with the FDA since March 2024: see the patent challenges.
Approved by the FDA
Not yet. The FDA has not approved a generic ozanimod hydrochloride. Final approval often comes close to the day a generic can be sold.
For Sale in Pharmacies
Not yet. No company lists a generic ozanimod hydrochloride for sale with the FDA.
Sources: how many companies have applied, from court records and company announcements; approved generics from the FDA Orange Book; tentative approvals from Drugs@FDA; what is for sale from the FDA NDC Directory. The FDA does not disclose an application before it approves it (21 CFR 314.430).
Zeposia Price: What Pharmacies Pay and What Generics Usually Do
What a Generic Could Cost
How we estimate it. The national survey of what pharmacies pay (NADAC) has no recent price for Zeposia, so we cannot show dollars. Here is the FDA’s finding of how far the price pharmacies pay usually falls as generic companies join: about 31% with one company, 44% with two, 73% with four and over 95% with six or more (the typical drop for every drug whose first generic came out from 2015 to 2017).
Median prices pharmacies paid for the generic (invoice prices), compared with the brand’s price before generic entry, from FDA’s 2019 analysis “Generic Competition and Drug Prices”. At the manufacturer’s price FDA found steeper drops (about 39%, 54%, 79% and over 95%), the figures quoted elsewhere on this tracker. A typical pattern, not a price quote for this medicine.
What Medicare and Medicaid Spend on Zeposia
Big public spending is part of why generic makers line up for a medicine, and why its first generic matters beyond the pharmacy counter. Figures are before manufacturer rebates, which are confidential.
Medicare Part D Spending
What Medicare drug plans spent on Zeposia, before manufacturer rebates.
- $28.1M
- January to March 2026, the latest CMS has posted
For 1,092 people, about $11,152 per prescription fill - $119.2M
- 2025, the whole year
For 1,475 people, about $10,946 per prescription fill
See the numbers
| Period | Spending | People | Per fill |
|---|---|---|---|
| January to March 2026 | $28,112,943 | 1,092 | $11,151.50 |
| 2025 | $119,233,324 | 1,475 | $10,945.87 |
Source: CMS Medicare Part D Spending by Drug, matched by the brand name Zeposia only, so no generic is counted in it. What CMS says it is used for: This medication is used to treat multiple sclerosis (MS). Ozanimod is not a cure for MS but it is thought to help by preventing immune system cells (lymphocytes) from attacking the nerves in your brain and spinal cord.
Medicaid Prescriptions by Quarter
5,162 prescriptions in the four quarters to Q1 2026, $52.3M paid.
See the numbers
| Quarter | Prescriptions | Medicaid paid |
|---|---|---|
| Q1 2026 | 1,179 | $12,382,160 |
| Q4 2025 | 1,343 | $13,402,394 |
| Q3 2025 | 1,319 | $13,343,275 |
| Q2 2025 | 1,321 | $13,164,307 |
| Q1 2025 | 1,330 | $13,126,476 |
Source: CMS Medicaid State Drug Utilization Data, over Zeposia’s own package codes.
Zeposia Strengths and Forms
| Strength | Form | How it is taken | Approved | Status |
|---|---|---|---|---|
| EQ 0.23MG BASE | Capsule | Oral | March 2020 | Prescription reference product |
| EQ 0.46MG BASE | Capsule | Oral | March 2020 | Prescription reference product |
| EQ 0.92MG BASE | Capsule | Oral | March 2020 | Prescription reference product |
Source: FDA Orange Book, Bristol Myers Squibb Co. Listed for sale today by Celgene Corporation (FDA NDC Directory).
Zeposia NDC Codes and Packages
Each Zeposia package sold today has its own NDC, the product number printed on the box and on the pharmacy label. Open one to see that package’s details, what pharmacies pay for it and its patent timeline.
| NDC | Product | Package | Company |
|---|---|---|---|
| 59572-0820-30 | OZANIMOD HYDROCHLORIDE .92 mg/1 capsule | bottle of 30 capsules | Celgene Corporation |
| 59572-0820-30 | OZANIMOD HYDROCHLORIDE .92 mg/1 capsule | bottle of 30 capsules | Celgene Corporation |
| 59572-0820-97 | OZANIMOD HYDROCHLORIDE .92 mg/1 capsule | bottle of 30 capsules | Celgene Corporation |
| 59572-0810-07 | kit | 1 KIT in 1 BLISTER PACK * 1 CAPSULE in 1 BLISTER PACK * 1 CAPSULE in 1 BLISTER PACK | Celgene Corporation |
| 59572-0810-07 | kit | 1 KIT in 1 BLISTER PACK * 1 CAPSULE in 1 BLISTER PACK * 1 CAPSULE in 1 BLISTER PACK | Celgene Corporation |
| 59572-0810-97 | kit | 1 KIT in 1 BLISTER PACK * 1 CAPSULE in 1 BLISTER PACK * 1 CAPSULE in 1 BLISTER PACK | Celgene Corporation |
| 59572-0810-97 | kit | 1 KIT in 1 BLISTER PACK * 1 CAPSULE in 1 BLISTER PACK * 1 CAPSULE in 1 BLISTER PACK | Celgene Corporation |
| 59572-0890-28 | kit | 1 KIT in 1 CARTON * 1 CAPSULE in 1 BLISTER PACK * 21 CAPSULE in 1 BOTTLE, PLASTIC * 1 CAPSULE in 1 BLISTER PACK | Celgene Corporation |
Show the other 5 Zeposia packages
| NDC | Product | Package | Company |
|---|---|---|---|
| 59572-0890-28 | kit | 1 KIT in 1 CARTON * 1 CAPSULE in 1 BLISTER PACK * 21 CAPSULE in 1 BOTTLE, PLASTIC * 1 CAPSULE in 1 BLISTER PACK | Celgene Corporation |
| 59572-0890-91 | kit | 1 KIT in 1 CARTON * 1 CAPSULE in 1 BLISTER PACK * 1 CAPSULE in 1 BLISTER PACK * 30 CAPSULE in 1 BOTTLE, PLASTIC | Celgene Corporation |
| 59572-0890-97 | kit | 1 KIT in 1 CARTON * 1 CAPSULE in 1 BLISTER PACK * 1 CAPSULE in 1 BLISTER PACK * 30 CAPSULE in 1 BOTTLE, PLASTIC | Celgene Corporation |
| 59572-0890-98 | kit | 1 KIT in 1 CARTON * 1 CAPSULE in 1 BLISTER PACK * 21 CAPSULE in 1 BOTTLE, PLASTIC * 1 CAPSULE in 1 BLISTER PACK | Celgene Corporation |
| 59572-0890-98 | kit | 1 KIT in 1 CARTON * 1 CAPSULE in 1 BLISTER PACK * 21 CAPSULE in 1 BOTTLE, PLASTIC * 1 CAPSULE in 1 BLISTER PACK | Celgene Corporation |
Source: the FDA NDC Directory, current listings only. Only packages sold under Zeposia’s own FDA approval (NDA 209899) are listed, never a generic. Some codes belong to companies that repackage Zeposia: it is the same medicine in a different package.
What a Generic Zeposia Means for You
Nothing Changes Until It Is in Pharmacies
Until a generic is actually for sale, keep filling Zeposia as usual. When one arrives, there is nothing you need to sign up for.
Your Pharmacy May Switch You Automatically
Every state lets pharmacists fill a brand-name prescription with an FDA-approved generic rated as equivalent to it, and about 19 states require them to, unless your prescriber writes “dispense as written” or “brand medically necessary” on the prescription. Some states ask the pharmacist to tell you, or to get your OK first. A study of every state’s law has the details.
It Will Probably Look Different
US trademark law does not let a generic look exactly like the brand, so the color, shape or markings usually change. The active ingredient, strength and form are the same. An “authorized generic,” made by or for the brand’s own company, can look identical. The FDA explains.
Your Insurance May Change Too
Once a lower-cost version is available, many insurance plans charge more for the brand, or stop covering it. Your plan’s drug list (formulary) says how.
Until a generic is on US pharmacy shelves, be careful with websites that offer “generic Zeposia”. The FDA warns that unlicensed online pharmacies sell counterfeit and unapproved medicines; its BeSafeRx page shows how to check a pharmacy.
Questions people ask about Zeposia
Is there a generic for Zeposia right now?
No. As of October 9, 2026 no generic ozanimod hydrochloride is listed for sale in the FDA NDC Directory.
When will Zeposia go generic?
2033 to 2034 is the expected window, and that is probable but not certain. The brand company and a generic maker settled their patent fight and agreed on when a generic can launch. The last listed patent runs to September 2038; a court ruling or a settlement can bring a generic sooner.
Will generic ozanimod hydrochloride be the same as Zeposia?
Yes in the ways that matter: the same active ingredient, strength and form, with proof that it reaches your blood the same way. Inactive ingredients can differ, which is why some people notice a different look or taste.
How much will the generic cost?
Nobody can say for sure before launch. 2 companies have applied to the FDA to make it. In the FDA’s study of past launches, pharmacies paid about 44% less once two companies sold a generic. That is a pattern from past launches, not a prediction for this one.
Has the FDA approved a generic Zeposia?
Not yet. The FDA Orange Book lists no approved generic version of Zeposia.
When does the Zeposia patent expire?
The FDA Orange Book lists 5 patents for Zeposia; the last runs to September 2038. A patent date is not the launch date: settlements and court rulings often bring a generic earlier, and FDA approval or a company’s own plans can make it later. The expected window on this page (2033 to 2034) weighs all of that.
Has anyone challenged the Zeposia patents?
Yes. The first patent challenge to Zeposia reached the FDA in March 2024, from 3 companies on that first day. The FDA has not approved a first challenger’s generic yet. A patent challenge (a “Paragraph IV certification”) is a generic company telling the FDA that a patent listed for the brand is invalid or will not be infringed by its version. The first companies to file one can earn a 180-day head start, during which the FDA cannot approve the generics that filed after them.
Changes to This Projection
- First generic expected 2033 to 2034 on this month’s schedule. A line is added here whenever a monthly update moves the month, the reason or how sure it is.
Every change to the expected month is logged here with the month we saw it.
Also Going Generic
- JentaduetoLinagliptin and Metformin HydrochlorideJuly to December 2026
- SolosecSecnidazoleSeptember 2027
- Arcapta NeohalerIndacaterol MaleateOctober 2028
- VraylarCariprazine HydrochlorideMarch 2030
- OngentysOpicaponeDecember 2032
- ElyxybCelecoxibMay 2036
About Zeposia
- Generic name ozanimod hydrochloride
- How it is taken By mouth
- Company Bristol Myers Squibb Co
- Patent challenges Since March 2024 (FDA)
- More drugs Brand-name drugs starting with Z
- Have a question? A pharmacist answers, free. Ask about Zeposia
Sources. The expected month: FDA Paragraph IV Patent Certifications list, federal court records, company announcements and securities filings (settlement dates, launch plans, sales). The record on this page: FDA Orange Book, Drugs@FDA (tentative approvals), FDA NDC Directory, FDA Paragraph IV Patent Certifications list, CMS Medicare Part D Spending by Drug, Medicaid State Drug Utilization Data, FDA, Generic Competition and Drug Prices (2019). Updated October 9, 2026. Information, not medical advice.